Table 1.

Key questions

1. What is the case definition of COVID-19 associated pulmonary aspergillosis?

2. What is the optimal approach towards diagnosing or refuting CAPA in patients with COVID-19?

3. What is the reported prevalence of Aspergillus pneumonia in patients with COVID-19?

4. What are the host-/risk factors that are associated with COVID-19 associated pulmonary aspergillosis (CAPA)?

5. Is antifungal therapy indicated in patients suspected of CAPA?

6. How should invasive Aspergillus tracheobronchitis be managed in CAPA patients?

7. What is the role of immunomodulating agents in the management of CAPA in ICU patients?